Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia
Background: It would be clinically useful to prospectively identify the risk of disease progression in chronic myeloid leukaemia (CML). Overexpression of cancerous inhibitor of protein phosphatase 2A (PP2A) (CIP2A) protein is an adverse prognostic indicator in many cancers. Methods: We examined CIP2...
Main Authors: | Richard E. Clark, Ammar A. Basabrain, Gemma M. Austin, Alison K. Holcroft, Sandra Loaiza, Jane F. Apperley, Christopher Law, Laura Scott, Alexandra D. Parry, Laura Bonnett, Claire M. Lucas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/9/2155 |
Similar Items
-
Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients
by: Esraa K. Al-Amleh, et al.
Published: (2022-08-01) -
Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011-12-01) -
Blast crisis in chronic myeloid leukemia in a 22-month-old child: Is this the youngest child with chronic myeloid leukaemia from India?
by: Sharanjit Singh Toor, et al.
Published: (2023-01-01) -
Evaluation of Imatinib adherence in chronic myeloid leukemia patients in Babylon Province, Iraq
by: Athmar Kadhim Gatea, et al.
Published: (2023-01-01) -
Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients
by: Sarah Allegra, et al.
Published: (2023-09-01)